Acquired Bleeding Disorder — Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever
Citation(s)
A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Comparison of Recombinant Factor VIIa (NovoSeven®) and Standard Haemostatic Replacement Therapy in Patients With Dengue Haemorrhagic Fever